Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28776444 | 0.78 | CYP2C9 (0.37) | KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL22774033 | 0.75 | GRM5 (0.34) | GRM5KEAP1NFE2L2 | |
| SCHEMBL22774826 | 0.74 | PDE4A (0.42) | PDE4AMAPK1 | |
| SCHEMBL29576542 | 0.74 | PDE4A (0.42) | PDE4AMAPK1 | |
| SCHEMBL8486770 | 0.73 | PDE4A (0.33) | PDE4AMAPK1 | |
| SCHEMBL29577112 | 0.73 | PDE4A (0.33) | PDE4AMAPK1 | |
| SCHEMBL22795691 | 0.66 | MAOA (0.34) | GRM5 | |
| SCHEMBL4365445 | 0.65 | KEAP1 (0.35) | KEAP1NFE2L2 | |
| SCHEMBL19971066 | 0.65 | PDE4A (0.36) | PDE4AKDM4EALDH1A1POLBGRM5 | |
| SCHEMBL22774193 | 0.64 | TOP2A (0.50) | KDM4EALDH1A1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2025-10-09 | — | — | US | disclosed |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2025-07-01 | — | — | US | disclosed |
| EP-3983078-B1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2023-11-15 | — | — | EP | disclosed |
| US-20230076506-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-03-09 | — | — | US | disclosed |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
| EP-4073063-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| EP-4073062-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-08-11 | — | — | US | disclosed |
| CN-114787148-A | Functionalized heterocyclic compounds as modulators of interferon gene Stimulators (STING) | 雷沃医疗有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114787147-A | Heterocyclic compounds as modulators of interferon gene Stimulators (STING) | 雷沃医疗有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3983078-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950473-A | Next generation modulators of interferon gene Stimulators (STING) | 雷沃医疗有限公司 | 2022-01-18 | — | — | CN | disclosed |
| WO-2021116446-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116446-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021116451-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020249773-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251082-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | PDE4A 26/4885KDM4E 4160/4885ALDH1A1 4562/4885 |
| US-12344606-B2 | Next-generation modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | PDE4A 26/4885KDM4E 4160/4885ALDH1A1 4562/4885 |
| US-20250313561-A1 | NEXT-GENERATION MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | PDE4A 26/4885KDM4E 4160/4885ALDH1A1 4562/4885 |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | PDE4A 226/4885KDM4E 2817/4885ALDH1A1 3577/4885 |
| US-20230076506-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | PDE4A 38/4885KDM4E 4302/4885ALDH1A1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.